{
  "schemaVersion": 1,
  "organisationId": "O-66f0da09a0a44cb9bcbd9f53969a9e3d",
  "slug": "argenx",
  "name": "ARGENX",
  "updatedAt": "2026-03-20T04:19:15.499148Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Founded in 2008, argenx is a global, commercial-stage biotechnology company focused on discovering, developing and commercializing antibody-based immunology therapies for patients with severe autoimmune diseases.[P-e7d5474a4f5f4b07afe032ffb01691b6][P-526fc22f23794b85889f03aaa4b990c3][P-7913034b726d40de92cbab081809231b] The company’s mission is to transform the lives of patients by translating immunology breakthroughs into novel antibody-based medicines and delivering transformative treatments globally.[P-e772e765aa46440db597b014c5712836][P-31187a63357543e495a82a3b51ee501b]\n\nargenx’s current commercial portfolio is centered on VYVGART and VYVGART SC, and its broader pipeline is built on proprietary antibody-engineering capabilities and the efgartigimod program across multiple autoimmune indications.[P-4a35e4d7d3e34600abea489bc73d1e7a][P-27d0b0ff84cb4f9ab3c220e1ae80a659][P-297ce62d0c33469cadca6cd00364cf35] The company has an international footprint, with product sales led by the United States and additional sales in Japan, China and other markets, alongside subsidiaries across Europe, North America, Asia and Australia and offices including Amsterdam, Boston and Tokyo.[T-4b6cba4160f24a68a4f1e7cc7b5e4638][T-ea38c78fb3f94c25b00bf9f0bd47e346][P-c4552ee93d88453f932ca49eae1d2d20] In 2024, argenx reported $2.186 billion in product net sales and $2.252 billion in total operating income, and it employed 1,599 people worldwide, with its largest employee bases in the United States and Belgium.[T-5235d33ecc70440c95b026528da174d5][P-526fc22f23794b85889f03aaa4b990c3][T-979aa3c9241d4b7aaede27e4e8b29369]\n[P-e7d5474a4f5f4b07afe032ffb01691b6][P-526fc22f23794b85889f03aaa4b990c3][P-7913034b726d40de92cbab081809231b][P-e772e765aa46440db597b014c5712836][P-31187a63357543e495a82a3b51ee501b][P-4a35e4d7d3e34600abea489bc73d1e7a][P-27d0b0ff84cb4f9ab3c220e1ae80a659][P-297ce62d0c33469cadca6cd00364cf35][T-4b6cba4160f24a68a4f1e7cc7b5e4638][T-ea38c78fb3f94c25b00bf9f0bd47e346][P-c4552ee93d88453f932ca49eae1d2d20][T-5235d33ecc70440c95b026528da174d5][T-979aa3c9241d4b7aaede27e4e8b29369]",
      "updatedAt": "2026-03-20T04:19:15.499148Z"
    },
    {
      "type": "PRODUCTS",
      "text": "argenx’s marketed product portfolio is centered on efgartigimod, an FcRn blocker sold in two formulations: VYVGART for intravenous use and a subcutaneous version marketed as VYVGART HYTRULO in the U.S. and China, VYVGART in the EU, VYVGART SC in the UK and Israel, and VYVDURA in Japan. Efgartigimod is described as a human IgG1 Fc fragment with ABDEG mutations designed to bind FcRn, reduce IgG recycling, and increase IgG degradation. The subcutaneous product combines efgartigimod alfa with recombinant human hyaluronidase PH20 using Halozyme’s ENHANZE drug-delivery technology. Approved uses include generalized myasthenia gravis in multiple markets, with additional approvals for chronic inflammatory demyelinating polyneuropathy for the subcutaneous product in the U.S., China, and Japan, and immune thrombocytopenia for intravenous VYVGART in Japan. [P-e5c170b6abe34ed989f1f4374c779112][P-81fa3d0095284d5abded284a64bb93f3][P-4921e9849b5945b68e2fa90261916128][P-9ae3a781be8c40029a79dad309e4f9ea]\n\nThese products account for nearly all of argenx’s current commercial performance. Product net sales were $2.19 billion in 2024, versus total operating income of $2.25 billion, implying roughly 97% of operating income came from product sales; the company states that these sales mainly consist of VYVGART and VYVGART SC sold in the U.S., Japan, EMEA, and China. [T-aa96cb9db772487d882683e12b001701][T-bc25ee659cf74a778ed12e6a61995ded][P-80901bf22d504bd39b0e7dcd53dabc42]\n\nBeyond the marketed franchise, argenx’s named product candidates include empasiprubart, a monoclonal antibody targeting complement component C2 that incorporates NHANCE mutations to capture and clear free C2 through FcRn-mediated recycling, and ARGX-119, which is being studied in congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company also lists earlier-stage candidates including ARGX-213, which targets FcRn, ARGX-121, which targets IgA, ARGX-220, which is intended to broaden immune-system targeting, and ARGX-109, which targets IL-6. [P-a87f434ab0a64ecabfecca0d38ce6792][P-3ae3ffc46eeb4a2a9e1481c99b156a47][P-81c6e446cf3a4cd5b53d72f4a1b24613][P-2c7455e9d8004c75ad9aef169fcd970b]\n[P-e5c170b6abe34ed989f1f4374c779112][P-81fa3d0095284d5abded284a64bb93f3][P-4921e9849b5945b68e2fa90261916128][P-9ae3a781be8c40029a79dad309e4f9ea][T-aa96cb9db772487d882683e12b001701][T-bc25ee659cf74a778ed12e6a61995ded][P-80901bf22d504bd39b0e7dcd53dabc42][P-a87f434ab0a64ecabfecca0d38ce6792][P-3ae3ffc46eeb4a2a9e1481c99b156a47][P-81c6e446cf3a4cd5b53d72f4a1b24613][P-2c7455e9d8004c75ad9aef169fcd970b]",
      "updatedAt": "2026-03-20T04:19:15.499148Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "argenx’s commercial footprint is concentrated in the United States, which generated $1.896 billion of 2024 product net sales, or about 86.7% of the total. Japan was the next-largest market at $89.4 million, or about 4.1%, followed by China at $39.2 million, or about 1.8%, while the rest of the world contributed $161.2 million, or about 7.4%; sales in the Netherlands were immaterial. This indicates a revenue base that is heavily weighted to the U.S., with additional but much smaller contributions from Asia and other international markets.[P-17505d368e9344418205045992002a44][P-a780f441e574462b9802afc6c5cd6e3a]\n\nOperationally, argenx maintains offices across North America, Europe, and Asia, including Amsterdam, Boston, Tokyo, Geneva, Munich, Issy-Les-Moulineaux, Vaughan (Ontario), Gerrards Cross, and Milan.[P-c4552ee93d88453f932ca49eae1d2d20] Its workforce is more geographically diversified than its sales base: as of December 31, 2024, it employed 1,599 people, with 694 in the United States (43.4%), 466 in Belgium (29.1%), and 139 in Japan (8.7%), with additional employees in Switzerland, the UK, Germany, France, the Netherlands, Italy, Spain, Canada, and other locations.[P-7fcb658375f4491e9f63bda39cdc09d0] The company also has legal entities or registered offices in a broad set of countries including Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Portugal, Spain, Switzerland, the UK, and the U.S., reflecting a multi-country operating structure alongside its U.S.-led commercial exposure.[T-ea38c78fb3f94c25b00bf9f0bd47e346]\n[P-17505d368e9344418205045992002a44][P-a780f441e574462b9802afc6c5cd6e3a][P-c4552ee93d88453f932ca49eae1d2d20][P-7fcb658375f4491e9f63bda39cdc09d0][T-ea38c78fb3f94c25b00bf9f0bd47e346]",
      "updatedAt": "2026-03-20T04:19:15.499148Z"
    },
    {
      "type": "SEGMENTS",
      "text": "argenx does not report multiple operating segments. It states that it manages its activities and operates as one business unit, does not distinguish different business or geographical segments in internal reporting, and identifies the Board of Directors as the chief operating decision-maker. In practice, this means 100% of the company’s business is reported within a single operating segment.[P-f88cb27b2b774f46bf5a0d59c49adf92] That segment is focused on the discovery, development and commercialization of immunology therapies for patients with severe autoimmune diseases.[P-526fc22f23794b85889f03aaa4b990c3]\n\nAs supplementary disclosure rather than formal segment reporting, argenx’s 2024 operating income was derived primarily from product net sales, which represented about 97.1% of total operating income, with collaboration revenue at about 0.2% and other operating income at about 2.7%.[T-bc25ee659cf74a778ed12e6a61995ded] The company also provides a geographic split for product net sales: the United States accounted for about 86.7%, Japan 4.1%, China 1.8%, and the rest of the world 7.4%, with the Netherlands immaterial.[P-17505d368e9344418205045992002a44][T-aa96cb9db772487d882683e12b001701]\n[P-f88cb27b2b774f46bf5a0d59c49adf92][P-526fc22f23794b85889f03aaa4b990c3][T-bc25ee659cf74a778ed12e6a61995ded][P-17505d368e9344418205045992002a44][T-aa96cb9db772487d882683e12b001701]",
      "updatedAt": "2026-03-20T04:19:15.499148Z"
    },
    {
      "type": "HISTORY",
      "text": "argenx was founded on April 25, 2008 in the Netherlands as arGEN-X B.V.; Tim Van Hauwermeiren co-founded the company in 2008 and became chief executive in July of that year.[P-182bf5962cf747bcb31888e49ec5f033][P-e7d5474a4f5f4b07afe032ffb01691b6] The company converted to a public limited company in May 2014 and listed its shares on Euronext Brussels in July 2014.[P-182bf5962cf747bcb31888e49ec5f033] In April 2016 it changed its legal name to argenx N.V., and in April 2017 it became argenx SE, followed by its Nasdaq IPO in New York.[P-182bf5962cf747bcb31888e49ec5f033]\n\nAfter its early years focused on building its antibody platform and pipeline, argenx reached its first major commercial milestone in December 2021, when the FDA approved VYVGART for generalized myasthenia gravis.[P-229bb6bfa2b54d81aacc8040ffd0e759][P-78b2502f5c78461d87b137f41f5ac499] VYVGART was then launched in the United States in January 2022, in Japan in May 2022, and in Germany in September 2022, marking the company’s first global product rollout.[P-e1745b7b2c83455e9541d88930a77e50][P-229bb6bfa2b54d81aacc8040ffd0e759] In June 2023, argenx expanded that franchise with U.S. approval and launch of the subcutaneous version, VYVGART HYTRULO.[P-a5157f2f7726401590bc50b66563a51d]\n[P-182bf5962cf747bcb31888e49ec5f033][P-e7d5474a4f5f4b07afe032ffb01691b6][P-229bb6bfa2b54d81aacc8040ffd0e759][P-78b2502f5c78461d87b137f41f5ac499][P-e1745b7b2c83455e9541d88930a77e50][P-a5157f2f7726401590bc50b66563a51d]",
      "updatedAt": "2026-03-20T04:19:15.499148Z"
    }
  ],
  "sources": [
    {
      "id": "P-e7d5474a4f5f4b07afe032ffb01691b6",
      "href": "https://app.finbar.com/go?id=P-e7d5474a4f5f4b07afe032ffb01691b6",
      "label": "ARGENX — Full financial report (2024 Y), p136",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 136
    },
    {
      "id": "P-526fc22f23794b85889f03aaa4b990c3",
      "href": "https://app.finbar.com/go?id=P-526fc22f23794b85889f03aaa4b990c3",
      "label": "ARGENX — Full financial report (2024 Y), p313",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 313
    },
    {
      "id": "P-7913034b726d40de92cbab081809231b",
      "href": "https://app.finbar.com/go?id=P-7913034b726d40de92cbab081809231b",
      "label": "ARGENX — Full financial report (2024 Y), p26",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 26
    },
    {
      "id": "P-e772e765aa46440db597b014c5712836",
      "href": "https://app.finbar.com/go?id=P-e772e765aa46440db597b014c5712836",
      "label": "ARGENX — Full financial report (2024 Y), p313",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 313
    },
    {
      "id": "P-31187a63357543e495a82a3b51ee501b",
      "href": "https://app.finbar.com/go?id=P-31187a63357543e495a82a3b51ee501b",
      "label": "ARGENX — Full financial report (2024 Y), p350",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 350
    },
    {
      "id": "P-4a35e4d7d3e34600abea489bc73d1e7a",
      "href": "https://app.finbar.com/go?id=P-4a35e4d7d3e34600abea489bc73d1e7a",
      "label": "ARGENX — Full financial report (2024 Y), p207",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 207
    },
    {
      "id": "P-27d0b0ff84cb4f9ab3c220e1ae80a659",
      "href": "https://app.finbar.com/go?id=P-27d0b0ff84cb4f9ab3c220e1ae80a659",
      "label": "ARGENX — Full financial report (2024 Y), p14",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 14
    },
    {
      "id": "P-297ce62d0c33469cadca6cd00364cf35",
      "href": "https://app.finbar.com/go?id=P-297ce62d0c33469cadca6cd00364cf35",
      "label": "ARGENX — Full financial report (2024 Y), p15",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 15
    },
    {
      "id": "T-4b6cba4160f24a68a4f1e7cc7b5e4638",
      "href": "https://app.finbar.com/go?id=T-4b6cba4160f24a68a4f1e7cc7b5e4638",
      "label": "ARGENX — Full financial report (2024 Y), p272",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 272
    },
    {
      "id": "T-ea38c78fb3f94c25b00bf9f0bd47e346",
      "href": "https://app.finbar.com/go?id=T-ea38c78fb3f94c25b00bf9f0bd47e346",
      "label": "ARGENX — Full financial report (2024 Y), p315",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 315
    },
    {
      "id": "P-c4552ee93d88453f932ca49eae1d2d20",
      "href": "https://app.finbar.com/go?id=P-c4552ee93d88453f932ca49eae1d2d20",
      "label": "ARGENX — Full financial report (2024 Y), p222",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 222
    },
    {
      "id": "T-5235d33ecc70440c95b026528da174d5",
      "href": "https://app.finbar.com/go?id=T-5235d33ecc70440c95b026528da174d5",
      "label": "ARGENX — Full financial report (2024 Y), p245",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 245
    },
    {
      "id": "T-979aa3c9241d4b7aaede27e4e8b29369",
      "href": "https://app.finbar.com/go?id=T-979aa3c9241d4b7aaede27e4e8b29369",
      "label": "ARGENX — Full financial report (2024 Y), p348",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 348
    },
    {
      "id": "P-e5c170b6abe34ed989f1f4374c779112",
      "href": "https://app.finbar.com/go?id=P-e5c170b6abe34ed989f1f4374c779112",
      "label": "ARGENX — Full financial report (2024 Y), p36",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 36
    },
    {
      "id": "P-81fa3d0095284d5abded284a64bb93f3",
      "href": "https://app.finbar.com/go?id=P-81fa3d0095284d5abded284a64bb93f3",
      "label": "ARGENX — Full financial report (2024 Y), p35",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 35
    },
    {
      "id": "P-4921e9849b5945b68e2fa90261916128",
      "href": "https://app.finbar.com/go?id=P-4921e9849b5945b68e2fa90261916128",
      "label": "ARGENX — Full financial report (2024 Y), p48",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 48
    },
    {
      "id": "P-9ae3a781be8c40029a79dad309e4f9ea",
      "href": "https://app.finbar.com/go?id=P-9ae3a781be8c40029a79dad309e4f9ea",
      "label": "ARGENX — Full financial report (2024 Y), p33",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 33
    },
    {
      "id": "T-aa96cb9db772487d882683e12b001701",
      "href": "https://app.finbar.com/go?id=T-aa96cb9db772487d882683e12b001701",
      "label": "ARGENX — Full financial report (2024 Y), p213",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 213
    },
    {
      "id": "T-bc25ee659cf74a778ed12e6a61995ded",
      "href": "https://app.finbar.com/go?id=T-bc25ee659cf74a778ed12e6a61995ded",
      "label": "ARGENX — Full financial report (2024 Y), p213",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 213
    },
    {
      "id": "P-80901bf22d504bd39b0e7dcd53dabc42",
      "href": "https://app.finbar.com/go?id=P-80901bf22d504bd39b0e7dcd53dabc42",
      "label": "ARGENX — Full financial report (2024 Y), p209",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 209
    },
    {
      "id": "P-a87f434ab0a64ecabfecca0d38ce6792",
      "href": "https://app.finbar.com/go?id=P-a87f434ab0a64ecabfecca0d38ce6792",
      "label": "ARGENX — Full financial report (2024 Y), p44",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 44
    },
    {
      "id": "P-3ae3ffc46eeb4a2a9e1481c99b156a47",
      "href": "https://app.finbar.com/go?id=P-3ae3ffc46eeb4a2a9e1481c99b156a47",
      "label": "ARGENX — Full financial report (2024 Y), p44",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 44
    },
    {
      "id": "P-81c6e446cf3a4cd5b53d72f4a1b24613",
      "href": "https://app.finbar.com/go?id=P-81c6e446cf3a4cd5b53d72f4a1b24613",
      "label": "ARGENX — Full financial report (2024 Y), p47",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 47
    },
    {
      "id": "P-2c7455e9d8004c75ad9aef169fcd970b",
      "href": "https://app.finbar.com/go?id=P-2c7455e9d8004c75ad9aef169fcd970b",
      "label": "ARGENX — Full financial report (2024 Y), p47",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 47
    },
    {
      "id": "P-17505d368e9344418205045992002a44",
      "href": "https://app.finbar.com/go?id=P-17505d368e9344418205045992002a44",
      "label": "ARGENX — Full financial report (2024 Y), p272",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 272
    },
    {
      "id": "P-a780f441e574462b9802afc6c5cd6e3a",
      "href": "https://app.finbar.com/go?id=P-a780f441e574462b9802afc6c5cd6e3a",
      "label": "ARGENX — Full financial report (2024 Y), p272",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 272
    },
    {
      "id": "P-7fcb658375f4491e9f63bda39cdc09d0",
      "href": "https://app.finbar.com/go?id=P-7fcb658375f4491e9f63bda39cdc09d0",
      "label": "ARGENX — Full financial report (2024 Y), p223",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 223
    },
    {
      "id": "P-f88cb27b2b774f46bf5a0d59c49adf92",
      "href": "https://app.finbar.com/go?id=P-f88cb27b2b774f46bf5a0d59c49adf92",
      "label": "ARGENX — Full financial report (2024 Y), p272",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 272
    },
    {
      "id": "P-182bf5962cf747bcb31888e49ec5f033",
      "href": "https://app.finbar.com/go?id=P-182bf5962cf747bcb31888e49ec5f033",
      "label": "ARGENX — Full financial report (2021 Y), p17",
      "documentId": "D-eac020ad7c6249df8eb183d50749ef63",
      "page": 17
    },
    {
      "id": "P-229bb6bfa2b54d81aacc8040ffd0e759",
      "href": "https://app.finbar.com/go?id=P-229bb6bfa2b54d81aacc8040ffd0e759",
      "label": "ARGENX — Full financial report (2024 Y), p207",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 207
    },
    {
      "id": "P-78b2502f5c78461d87b137f41f5ac499",
      "href": "https://app.finbar.com/go?id=P-78b2502f5c78461d87b137f41f5ac499",
      "label": "ARGENX — Full financial report (2021 Y), p21",
      "documentId": "D-eac020ad7c6249df8eb183d50749ef63",
      "page": 21
    },
    {
      "id": "P-e1745b7b2c83455e9541d88930a77e50",
      "href": "https://app.finbar.com/go?id=P-e1745b7b2c83455e9541d88930a77e50",
      "label": "ARGENX — Full financial report (2022 Y), p41",
      "documentId": "D-2748874b4f674c768e6c52546eb7efdb",
      "page": 41
    },
    {
      "id": "P-a5157f2f7726401590bc50b66563a51d",
      "href": "https://app.finbar.com/go?id=P-a5157f2f7726401590bc50b66563a51d",
      "label": "ARGENX — Full financial report (2024 Y), p34",
      "documentId": "D-79273e0b096d4a3b83bf0fe815fa9a6e",
      "page": 34
    }
  ]
}